Cyramza Drug Interactions
Currently displaying 99 drugs known to have a major interaction with Cyramza (ramucirumab).
- 99 major drug interactions
- 38 moderate drug interactions
Major interactions with Cyramza (ramucirumab)
Note: Showing generic names only.
A
- abciximab
- acalabrutinib
- ado-trastuzumab emtansine
- alteplase
- anagrelide
- anisindione
- anistreplase
- antithrombin (recombinant)
- antithrombin iii
- apixaban
- ardeparin
- argatroban
- aspirin
- avapritinib
B
C
D
- dabigatran
- dalteparin
- danaparoid
- dasatinib
- deferasirox
- defibrotide
- desirudin
- dextran 1
- dextran, high molecular weight
- dextran, low molecular weight
- diclofenac
- dicumarol
- diflunisal
- dipyridamole
- drotrecogin alfa
E
F
H
I
K
L
M
N
O
P
R
S
T
- tazemetostat
- tenecteplase
- ticagrelor
- ticlopidine
- tinzaparin
- tipranavir
- tirofiban
- tolmetin
- tositumomab
- treprostinil
U
V
W
Z
Cyramza disease interactions
There are 8 disease interactions with Cyramza (ramucirumab) which include:
- bleeding
- GI perforation
- hypothyroidism
- liver dysfunction
- hypertension
- PRES
- proteinuria
- thromboembolic disorders
More about Cyramza (ramucirumab)
- Cyramza consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: VEGF/VEGFR inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.